Houxiang Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Houxiang Hu has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
Xiaobo Wang
Academician Workstation and Department of Cardiology Affiliated Hospital of North Sichuan Medical College Nanchong 637000 China
7 shared publicationsHao Wang
5 shared publicationsJun Pu
Department of Cardiology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China
5 shared publicationsJunsong Guo
5 shared publicationsRongchuan Yue
Department of Cardiology, Affiliated Hospital of North Sichuan Medical College, Nanchong, People’s Republic of China
5 shared publicationsZhengping Yu
Department of Occupational Health, Third Military Medical University, Chongqing 400038, China
5 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1833723
Establishment and validation of a machine learning-based predictive model for in-hospital mortality risk in acute myocardial infarction patients complicated with diabetes mellitus
Objective: To develop and validate a machine learning-based (ML) predictive model for in-hospital mortality risk in patients with acute myocardial infarction (AMI) complicated by diabetes mellitus (DM). Methods: This retrospective study enrolled AMI patients with DM from the Affiliated Hospital of North Sichuan Medical College and the MIMIC-IV database. Common variables identified by both LASSO regression and the Boruta algorithm were selected as the final feature set. Utilizing the MIMIC-IV database, predictive models were constructed incorporating seven machine learning algorithms based on these common variables. The comprehensive performance of these models was evaluated through extensive metrics in both internal and external validation sets to identify the preferred model. Finally, the SHapley Additive exPlanations (SHAP) method was employed to quantitatively analyze and visually display the feature contributions of the preferred model. Results: Seven predictors were identified in this study through variable selection using two distinct methods, including heart rate, neutrophil count, monocyte count, neutrophil-to-lymphocyte ratio (NLR), serum albumin, total bilirubin, and urea nitrogen. Seven different ML models were built based on these predictors. Comprehensive performance evaluation across multiple metrics in both internal and external validation sets has shown that the XGBoost-based model achieved the numerically highest AUC and was selected as the preferred model. By employing the SHAP method for visual interpretation of this model, the interpretability and clinical credibility of the in-hospital mortality prediction model were significantly enhanced. This model can provide valuable auxiliary support in identifying high-risk patients and implementing early intervention measures. Conclusion: Interpretable machine learning models have been developed to predict in-hospital mortality risk in patients with AMI complicated by DM, providing insights into the influence of various features on the prediction outcome. Therefore, this model can serve as an exploratory and auxiliary risk stratification tool limited to clinical settings similar to our study cohorts, and it is not intended for generalized broad clinical application.
- 1 June 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1833723
Open AccessEstablishment and validation of a machine learning-based predictive model for in-hospital mortality risk in acute myocardial infarction patients complicated with diabetes mellitus
Objective: To develop and validate a machine learning-based (ML) predictive model for in-hospital mortality risk in patients with acute myocardial infarction (AMI) complicated by diabetes mellitus (DM). Methods: This retrospective study enrolled AMI patients with DM from the Affiliated Hospital of North Sichuan Medical College and the MIMIC-IV database. Common variables identified by both LASSO regression and the Boruta algorithm were selected as the final feature set. Utilizing the MIMIC-IV database, predictive models were constructed incorporating seven machine learning algorithms based on these common variables. The comprehensive performance of these models was evaluated through extensive metrics in both internal and external validation sets to identify the preferred model. Finally, the SHapley Additive exPlanations (SHAP) method was employed to quantitatively analyze and visually display the feature contributions of the preferred model. Results: Seven predictors were identified in this study through variable selection using two distinct methods, including heart rate, neutrophil count, monocyte count, neutrophil-to-lymphocyte ratio (NLR), serum albumin, total bilirubin, and urea nitrogen. Seven different ML models were built based on these predictors. Comprehensive performance evaluation across multiple metrics in both internal and external validation sets has shown that the XGBoost-based model achieved the numerically highest AUC and was selected as the preferred model. By employing the SHAP method for visual interpretation of this model, the interpretability and clinical credibility of the in-hospital mortality prediction model were significantly enhanced. This model can provide valuable auxiliary support in identifying high-risk patients and implementing early intervention measures. Conclusion: Interpretable machine learning models have been developed to predict in-hospital mortality risk in patients with AMI complicated by DM, providing insights into the influence of various features on the prediction outcome. Therefore, this model can serve as an exploratory and auxiliary risk stratification tool limited to clinical settings similar to our study cohorts, and it is not intended for generalized broad clinical application.
- 28 April 2026
- Published by Bentham Science Publishers Ltd. in Current Gene Therapy
- Vol. 26, 1-16
Sotagliflozin Ameliorates LPS‑Induced Cardiomyocyte Injury by Regulating the PI3K‑Akt and Extracellular Matrix–Related Pathways
Objective: This study aimed to define the protective effects of sotagliflozin against lipopolysaccharide (LPS)-induced injury in H9C2 cardiomyocytes, and map the core molecular pathways driving these effects to support new therapeutic strategies for SRMI. Methods: H9C2 rat cardiomyocytes were divided into a control group, LPS-challenged group, and LPS-challenged groups treated with 10, 20, and 30 μM sotagliflozin. Label-free quantitative Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) proteomics, coupled with bioinformatic analyses, was performed to map the drugregulated molecular network. Cell Counting Kit-8 (CCK-8) assay, biochemical kits, quantitative Real-Time PCR (qRT-PCR), Western blotting, immunofluorescence staining, and JC-1 probe assay were used to assess cell viability, cytotoxicity, oxidative stress markers, expression of inflammatory cytokines and NLRP3 inflammasome-related molecules, and mitochondrial membrane potential, respectively. Results: Proteomic profiling quantified 10,270 stably expressed proteins across all samples. Principal Component Analysis (PCA) revealed that PC1 and PC2 cumulatively explained 50.33% of intergroup variance, with clear separation between control and LPS groups, a pattern partially reversed by sotagliflozin treatment. In total, 630 differentially expressed proteins (DEPs; 252 upregulated, 378 downregulated) were identified in the LPS vs control comparison, and 210 DEPs (116 upregulated, 94 downregulated) in the sotagliflozin vs LPS comparison, with 49 core overlapping DEPs that were dysregulated by LPS and normalized by sotagliflozin. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses showed that LPS challenge predominantly disrupted pathways, including extracellular matrix organization and the PI3K-Akt signaling cascade, which were targeted and restored by sotagliflozin. Functional validation demonstrated that sotagliflozin mitigated LPS-induced cardiomyocyte injury in a dose-dependent manner: it significantly improved cell viability (20 and 30 μM groups, P<0.01 and P<0.001, respectively), reduced lactate dehydrogenase (LDH) release (P<0.05 and P<0.001), and restored the antioxidant defense markers glutathione (GSH) and superoxide dismutase (SOD) (P<0.01 and P<0.001). Sotagliflozin also markedly downregulated mRNA levels of pro-inflammatory cytokines IL6, TNF, and NLRP3 (P<0.05 and P<0.01), and dose-dependently inhibited the aberrant upregulation of NLRP3 inflammasome activation markers NLRP3, cleaved Caspase-1, and cleaved IL-1β (30 μM group, P < 0.05), a regulatory effect further validated by immunofluorescence staining (P < 0.01). Additionally, sotagliflozin significantly ameliorated LPS-induced mitochondrial membrane potential collapse in cardiomyocytes (30 μM group, P<0.01). Discussion: SRMI is a major driver of adverse clinical outcomes in patients with sepsis, yet no disease-modifying targeted therapies have been successfully translated into clinical practice to date. Here, we present the first unbiased proteomic profiling of the cardioprotective effects of sotagliflozin, a dual SGLT1/2 inhibitor, in lipopolysaccharide (LPS)-injured cardiomyocytes, addressing a critical unmet need in defining its repurposing potential for SRMI. Our data demonstrate that sotagliflozin exerts concentration-dependent protective effects against LPS-induced cardiomyocyte injury, characterized by mitigated oxidative stress, suppressed inflammatory responses (including inhibition of NLRP3 inflammasome activation at high concentrations), and preserved mitochondrial function. At the molecular level, sotagliflozin reverses LPS-induced proteomic dysregulation in cardiomyocytes, with the PI3K-Akt signaling cascade and ECM homeostasis identified as its two core regulatory axes. Dysregulation of the prosurvival, anti-inflammatory, and antioxidant PI3K-Akt pathway is closely associated with concurrent amelioration of multiple SRMI-related pathological phenotypes, from reduced cell death to preserved mitochondrial function. We further identify ECM organization as a previously unrecognized, exploratory regulatory target of sotagliflozin in SRMI, extending our understanding of its cardioprotective actions beyond its well-characterized metabolic effects. The 49 core DEPs whose LPS-induced dysregulation is reversed by sotagliflozin, identified herein, not only delineate the molecular basis of its protective effects but also represent promising novel candidate targets for SRMI gene therapy. The precise causal regulatory mechanisms underpinning these effects remain to be validated in future in vivo studies and functional genomic experiments. Conclusion: Sotagliflozin exerts cardioprotective effects against LPS-induced myocardial injury in H9C2 cardiomyocytes. This protection is mediated by the regulation of 49 core DEPs and key signaling pathways, most notably the PI3K/Akt pathway, which in turn attenuates excessive inflammatory responses, restores cellular redox balance, and ameliorates mitochondrial dysfunction.
- 28 April 2026
- Published by Bentham Science Publishers Ltd. in Current Gene Therapy
- Vol. 26, 1-16
Sotagliflozin Ameliorates LPS‑Induced Cardiomyocyte Injury by Regulating the PI3K‑Akt and Extracellular Matrix–Related Pathways
Objective: This study aimed to define the protective effects of sotagliflozin against lipopolysaccharide (LPS)-induced injury in H9C2 cardiomyocytes, and map the core molecular pathways driving these effects to support new therapeutic strategies for SRMI. Methods: H9C2 rat cardiomyocytes were divided into a control group, LPS-challenged group, and LPS-challenged groups treated with 10, 20, and 30 μM sotagliflozin. Label-free quantitative Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) proteomics, coupled with bioinformatic analyses, was performed to map the drugregulated molecular network. Cell Counting Kit-8 (CCK-8) assay, biochemical kits, quantitative Real-Time PCR (qRT-PCR), Western blotting, immunofluorescence staining, and JC-1 probe assay were used to assess cell viability, cytotoxicity, oxidative stress markers, expression of inflammatory cytokines and NLRP3 inflammasome-related molecules, and mitochondrial membrane potential, respectively. Results: Proteomic profiling quantified 10,270 stably expressed proteins across all samples. Principal Component Analysis (PCA) revealed that PC1 and PC2 cumulatively explained 50.33% of intergroup variance, with clear separation between control and LPS groups, a pattern partially reversed by sotagliflozin treatment. In total, 630 differentially expressed proteins (DEPs; 252 upregulated, 378 downregulated) were identified in the LPS vs control comparison, and 210 DEPs (116 upregulated, 94 downregulated) in the sotagliflozin vs LPS comparison, with 49 core overlapping DEPs that were dysregulated by LPS and normalized by sotagliflozin. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses showed that LPS challenge predominantly disrupted pathways, including extracellular matrix organization and the PI3K-Akt signaling cascade, which were targeted and restored by sotagliflozin. Functional validation demonstrated that sotagliflozin mitigated LPS-induced cardiomyocyte injury in a dose-dependent manner: it significantly improved cell viability (20 and 30 μM groups, P<0.01 and P<0.001, respectively), reduced lactate dehydrogenase (LDH) release (P<0.05 and P<0.001), and restored the antioxidant defense markers glutathione (GSH) and superoxide dismutase (SOD) (P<0.01 and P<0.001). Sotagliflozin also markedly downregulated mRNA levels of pro-inflammatory cytokines IL6, TNF, and NLRP3 (P<0.05 and P<0.01), and dose-dependently inhibited the aberrant upregulation of NLRP3 inflammasome activation markers NLRP3, cleaved Caspase-1, and cleaved IL-1β (30 μM group, P < 0.05), a regulatory effect further validated by immunofluorescence staining (P < 0.01). Additionally, sotagliflozin significantly ameliorated LPS-induced mitochondrial membrane potential collapse in cardiomyocytes (30 μM group, P<0.01). Discussion: SRMI is a major driver of adverse clinical outcomes in patients with sepsis, yet no disease-modifying targeted therapies have been successfully translated into clinical practice to date. Here, we present the first unbiased proteomic profiling of the cardioprotective effects of sotagliflozin, a dual SGLT1/2 inhibitor, in lipopolysaccharide (LPS)-injured cardiomyocytes, addressing a critical unmet need in defining its repurposing potential for SRMI. Our data demonstrate that sotagliflozin exerts concentration-dependent protective effects against LPS-induced cardiomyocyte injury, characterized by mitigated oxidative stress, suppressed inflammatory responses (including inhibition of NLRP3 inflammasome activation at high concentrations), and preserved mitochondrial function. At the molecular level, sotagliflozin reverses LPS-induced proteomic dysregulation in cardiomyocytes, with the PI3K-Akt signaling cascade and ECM homeostasis identified as its two core regulatory axes. Dysregulation of the prosurvival, anti-inflammatory, and antioxidant PI3K-Akt pathway is closely associated with concurrent amelioration of multiple SRMI-related pathological phenotypes, from reduced cell death to preserved mitochondrial function. We further identify ECM organization as a previously unrecognized, exploratory regulatory target of sotagliflozin in SRMI, extending our understanding of its cardioprotective actions beyond its well-characterized metabolic effects. The 49 core DEPs whose LPS-induced dysregulation is reversed by sotagliflozin, identified herein, not only delineate the molecular basis of its protective effects but also represent promising novel candidate targets for SRMI gene therapy. The precise causal regulatory mechanisms underpinning these effects remain to be validated in future in vivo studies and functional genomic experiments. Conclusion: Sotagliflozin exerts cardioprotective effects against LPS-induced myocardial injury in H9C2 cardiomyocytes. This protection is mediated by the regulation of 49 core DEPs and key signaling pathways, most notably the PI3K/Akt pathway, which in turn attenuates excessive inflammatory responses, restores cellular redox balance, and ameliorates mitochondrial dysfunction.
- Open Access
- 12 February 2026
- Published by Springer Nature in Discover Nano
- Vol. 21 (1) , 39
Advances in nanomaterials for the diagnosis and treatment of ischemic heart disease
Ischemic heart disease (IHD) remains a leading cause of mortality worldwide. Despite timely reperfusion therapy, myocardial ischemia can still lead to ventricular remodeling, arrhythmia, and heart failure, contributing to the high prevalence of cardiovascular disease. Nanomaterials provides innovative technical methods and tools for precise clinical diagnosis and effective treatment through nanoscale control of materials and biological interactions. In this study, bibliometrics have been harnessed to explore the region and topic distribution characteristics of nanotechnology in the field of ischemic cardiomyopathy. The key directions in this field contain cardiac tissue engineering, biosensor, targeted drug delivery and molecular imaging. China and USA are the leading contributors in this filed. Recent literature demonstrates rapid growth in nanomaterial-based strategies and their broad application in preclinical models of IHD. However, only a limited number of nanomedicine products have progressed to clinical approval. This review summarizes the current advances in nanotechnology for IHD, highlights remaining challenges, and discusses future directions to facilitate clinical translation.
- 12 February 2026
- Published by Springer Nature in Discover Nano
- Vol. 21 (1) , 39
Open AccessAdvances in nanomaterials for the diagnosis and treatment of ischemic heart disease
Ischemic heart disease (IHD) remains a leading cause of mortality worldwide. Despite timely reperfusion therapy, myocardial ischemia can still lead to ventricular remodeling, arrhythmia, and heart failure, contributing to the high prevalence of cardiovascular disease. Nanomaterials provides innovative technical methods and tools for precise clinical diagnosis and effective treatment through nanoscale control of materials and biological interactions. In this study, bibliometrics have been harnessed to explore the region and topic distribution characteristics of nanotechnology in the field of ischemic cardiomyopathy. The key directions in this field contain cardiac tissue engineering, biosensor, targeted drug delivery and molecular imaging. China and USA are the leading contributors in this filed. Recent literature demonstrates rapid growth in nanomaterial-based strategies and their broad application in preclinical models of IHD. However, only a limited number of nanomedicine products have progressed to clinical approval. This review summarizes the current advances in nanotechnology for IHD, highlights remaining challenges, and discusses future directions to facilitate clinical translation.
- Open Access
- 20 February 2025
- Published by Wiley in Small Science
- Vol. 5 (5)
Understanding the Mechanism of Cardiotoxicity Induced by Nanomaterials: A Comprehensive Review
Nanomaterials have been vastly used in daily life. However, owing to their unique properties, nanomaterials also show potential side effects. Among the various organs affected by nanomaterials, the circulatory system stands out as particularly vulnerable, drawing additional attention to its cardiac toxicity. To address the cardiovascular nanotoxicity and further promote the safe use of nanotechnology, a comprehensive review of the cardiotoxicity induced by nanomaterials is provided. The review begins by identifying the current research trends and hotspots in this field via a bibliometric analysis. Subsequently, based on the objectively obtained research hotspots, the mechanism of cardiovascular nanotoxicity, including exposure route, membrane injury, ion disturbance, oxidative stress, inflammation, and cell death, is reviewed and discussed. Finally, current strategies for the mitigation of nanotoxicity are also proposed. The objective of this review is to assist readers in understanding the mechanism of cardiotoxicity induced by nanomaterials and to facilitate their safe application for human health.
- 20 February 2025
- Published by Wiley in Small Science
- Vol. 5 (5)
Open AccessUnderstanding the Mechanism of Cardiotoxicity Induced by Nanomaterials: A Comprehensive Review
Nanomaterials have been vastly used in daily life. However, owing to their unique properties, nanomaterials also show potential side effects. Among the various organs affected by nanomaterials, the circulatory system stands out as particularly vulnerable, drawing additional attention to its cardiac toxicity. To address the cardiovascular nanotoxicity and further promote the safe use of nanotechnology, a comprehensive review of the cardiotoxicity induced by nanomaterials is provided. The review begins by identifying the current research trends and hotspots in this field via a bibliometric analysis. Subsequently, based on the objectively obtained research hotspots, the mechanism of cardiovascular nanotoxicity, including exposure route, membrane injury, ion disturbance, oxidative stress, inflammation, and cell death, is reviewed and discussed. Finally, current strategies for the mitigation of nanotoxicity are also proposed. The objective of this review is to assist readers in understanding the mechanism of cardiotoxicity induced by nanomaterials and to facilitate their safe application for human health.
- Open Access
- 18 December 2024
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 11, 1493290
Cardiac cells and mesenchymal stem cells derived extracellular vesicles: a potential therapeutic strategy for myocardial infarction
Despite improvements in clinical outcomes of acute myocardial infarction (AMI), mortality rates remain high, indicating the need for further understanding of the pathogenesis and developing more effective cardiac protection strategies. Extracellular vesicles (EVs) carry proteins and noncoding RNAs (ncRNAs) derived from different cardiac cell populations, mainly including cardiomyocytes, endothelial cells, endothelial progenitor cells, cardiac progenitor cells, cardiosphere-derived cells, immune cells, fibroblasts and cardiac telocytes have vital roles under both physiological and pathological process such as myocardial infarction (MI). The content of EVs can also indicate the status of their parental cells and serve as a biomarker for monitoring the risk of cardiac injury. Examining these vesicles can offer fresh perspectives on the development of MI and assist in creating innovative treatments. Additionally, mesenchymal stem cells (MSCs) (MSC-EVs) derived EVs have been shown to have significant potential in cardiac regeneration. In this review, we will discuss the current understanding of the role of EVs in cardiac communication, with a focus on the perspectives of EVs from various cardiac cells and MSCs for their potential uses as cardiac therapies after MI.
- 18 December 2024
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 11, 1493290
Open AccessCardiac cells and mesenchymal stem cells derived extracellular vesicles: a potential therapeutic strategy for myocardial infarction
Despite improvements in clinical outcomes of acute myocardial infarction (AMI), mortality rates remain high, indicating the need for further understanding of the pathogenesis and developing more effective cardiac protection strategies. Extracellular vesicles (EVs) carry proteins and noncoding RNAs (ncRNAs) derived from different cardiac cell populations, mainly including cardiomyocytes, endothelial cells, endothelial progenitor cells, cardiac progenitor cells, cardiosphere-derived cells, immune cells, fibroblasts and cardiac telocytes have vital roles under both physiological and pathological process such as myocardial infarction (MI). The content of EVs can also indicate the status of their parental cells and serve as a biomarker for monitoring the risk of cardiac injury. Examining these vesicles can offer fresh perspectives on the development of MI and assist in creating innovative treatments. Additionally, mesenchymal stem cells (MSCs) (MSC-EVs) derived EVs have been shown to have significant potential in cardiac regeneration. In this review, we will discuss the current understanding of the role of EVs in cardiac communication, with a focus on the perspectives of EVs from various cardiac cells and MSCs for their potential uses as cardiac therapies after MI.
- 30 October 2024
- Published by Elsevier in Chemical Engineering Journal
- Vol. 500
A transdermal fullerenol emulsion-mediated angiogenesis mitigates radiation-induced skin injury
- 30 October 2024
- Published by Elsevier in Chemical Engineering Journal
- Vol. 500
A transdermal fullerenol emulsion-mediated angiogenesis mitigates radiation-induced skin injury
- Open Access
- 23 February 2024
- Published by Springer Nature in Applied Physics A
- Vol. 130 (3) , 1-11
Fullerenol as a novel therapeutic agent for sepsis-induced cardiomyocytes damage
Sepsis-induced myocardial damage (SIMD) is a serious complication of sepsis that affects cardiac function and prognosis. However, effective methods for the prevention and treatment of SIMD are presently lacking. This study reports the crucial function of fullerenols in protecting cardiomyocytes from septic injury. First, we applied the as-prepared fullerenols as an effective free radical scavenger and broad-spectrum anti-oxidant to protect against LPS-induced cardiomyocyte injury. Next, we verified their ability to downregulate IL-6, TNF-α, and ROS-dependent pyroptosis in AC16 induced by LPS. Finally, we observed that the protective mechanism of fullerenol against SIMD involves the regulation of the NFκB/iNOS/COX-2 pathway. This study presents a timely and essential investigation of the prevention and treatment of SIMD, providing new insights into the applications of fullerenols for therapeutic strategies.
- 23 February 2024
- Published by Springer Nature in Applied Physics A
- Vol. 130 (3) , 1-11
Open AccessFullerenol as a novel therapeutic agent for sepsis-induced cardiomyocytes damage
Sepsis-induced myocardial damage (SIMD) is a serious complication of sepsis that affects cardiac function and prognosis. However, effective methods for the prevention and treatment of SIMD are presently lacking. This study reports the crucial function of fullerenols in protecting cardiomyocytes from septic injury. First, we applied the as-prepared fullerenols as an effective free radical scavenger and broad-spectrum anti-oxidant to protect against LPS-induced cardiomyocyte injury. Next, we verified their ability to downregulate IL-6, TNF-α, and ROS-dependent pyroptosis in AC16 induced by LPS. Finally, we observed that the protective mechanism of fullerenol against SIMD involves the regulation of the NFκB/iNOS/COX-2 pathway. This study presents a timely and essential investigation of the prevention and treatment of SIMD, providing new insights into the applications of fullerenols for therapeutic strategies.
- Open Access
- 18 September 2023
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 24 (9) , 257
Analysis of Physician Compliance with Guideline-Directed Medical Therapy for Patients with Heart Failure with Reduced Ejection Fraction: A Real-World Study
Background: Although compliance with the guideline recommendations for heart failure (HF) is associated with improved survival, the effects of medication on clinical practice often fail to meet expectations due to physician and/or patient-related reasons that are unclear. This study analyzed physicians’ compliance with guideline-directed medical therapy (GDMT) based on real-world clinical data and identified risk factors of low compliance. Methods: This study included patients with HF, who were treated at the Affiliated Hospital of North Sichuan Medical College from July 2017 to June 2021. All patients were divided into high compliance, moderate compliance, and low compliance with GDMT groups. The proportion of patients receiving treatment in compliance with GDMT was analyzed, the relationship between compliance with GDMT and clinical outcomes was evaluated, and the risk factors of low compliance were identified. Results: Of all patients with HF included in the study, 498 (23.8%) had low compliance with GDMT, 1413 (67.4%) had moderate compliance with GDMT, and 185 (8.8%) had high compliance with GDMT. The readmission rate of patients in the moderate compliance with GDMT group was significantly higher than that in the high and low compliance groups (p = 0.028). There were no significant differences in the rates of severe cardiovascular disease among the three groups. The mortality rate of patients in the high compliance with GDMT group was significantly higher than that of the other groups (p < 0.001). We found that a history of hypertension; New York Heart Association (NYHA) classification (III and IV vs. I); and abnormal heart rate, high-sensitive troponin T (hsTnT), N-terminal prohormone of brain natriuretic peptide (NT-proBNP), uric acid, and left ventricular diastolic dysfunction (LVDD) were all significantly associated with low compliance with GDMT. Conclusions: The proportion of physicians’ compliance with GDMT in treating patients with HF is low. Risk factors of low compliance include hypertension; NYHA classification (III and IV vs. I); and abnormal heart rate, hsTnT, NT proBNP, uric acid, and LVDD.
- 18 September 2023
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 24 (9) , 257
Open AccessAnalysis of Physician Compliance with Guideline-Directed Medical Therapy for Patients with Heart Failure with Reduced Ejection Fraction: A Real-World Study
Background: Although compliance with the guideline recommendations for heart failure (HF) is associated with improved survival, the effects of medication on clinical practice often fail to meet expectations due to physician and/or patient-related reasons that are unclear. This study analyzed physicians’ compliance with guideline-directed medical therapy (GDMT) based on real-world clinical data and identified risk factors of low compliance. Methods: This study included patients with HF, who were treated at the Affiliated Hospital of North Sichuan Medical College from July 2017 to June 2021. All patients were divided into high compliance, moderate compliance, and low compliance with GDMT groups. The proportion of patients receiving treatment in compliance with GDMT was analyzed, the relationship between compliance with GDMT and clinical outcomes was evaluated, and the risk factors of low compliance were identified. Results: Of all patients with HF included in the study, 498 (23.8%) had low compliance with GDMT, 1413 (67.4%) had moderate compliance with GDMT, and 185 (8.8%) had high compliance with GDMT. The readmission rate of patients in the moderate compliance with GDMT group was significantly higher than that in the high and low compliance groups (p = 0.028). There were no significant differences in the rates of severe cardiovascular disease among the three groups. The mortality rate of patients in the high compliance with GDMT group was significantly higher than that of the other groups (p < 0.001). We found that a history of hypertension; New York Heart Association (NYHA) classification (III and IV vs. I); and abnormal heart rate, high-sensitive troponin T (hsTnT), N-terminal prohormone of brain natriuretic peptide (NT-proBNP), uric acid, and left ventricular diastolic dysfunction (LVDD) were all significantly associated with low compliance with GDMT. Conclusions: The proportion of physicians’ compliance with GDMT in treating patients with HF is low. Risk factors of low compliance include hypertension; NYHA classification (III and IV vs. I); and abnormal heart rate, hsTnT, NT proBNP, uric acid, and LVDD.
- 13 September 2023
- Published by Elsevier in Acta Biomaterialia
- Vol. 171, 37-67
Nanotechnology in coronary heart disease
- 13 September 2023
- Published by Elsevier in Acta Biomaterialia
- Vol. 171, 37-67
Nanotechnology in coronary heart disease
- 31 August 2023
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 15 (36) , 42139-42152
Lung Toxicity and Molecular Mechanisms of Lead-Based Perovskite Nanoparticles in the Respiratory System
Extensive applications across diverse fields. However, because of poor stability and relatively strong water solubility, the potential toxicity of Pb-PNPs released into the environment during their manufacture, usage, and disposal has attracted significant attention. Inhalation is a primary route through which human exposure to Pb-PNPs occurs. Herein, the toxic effects and underlying molecular mechanisms of Pb-PNPs in the respiratory system are investigated. The in vitro cytotoxicity of CsPbBr3 nanoparticles in BEAS-2B cells is studied using multiple bioassays and electron microscopy. CsPbBr3 nanoparticles of different concentrations induce excessive oxidative stress and cell apoptosis. Furthermore, CsPbBr3 nanoparticles specifically recruit the TGF-beta(1), which subsequently induces epithelial-mesenchymal transition. In addition, the biodistribution and lung toxicity of representative CsPbBr3 nanoparticles in ICR mice are investigated following intranasal administration. These findings indicate that CsPbBr3 nanoparticles significantly induce pulmonary inflammation and epithelial-mesenchymal transition and can even lead to pulmonary fibrosis in mouse models. Above findings expose the adverse effects and molecular mechanisms of Pb-PNPs in the lung, which broadens the safety data of Pb-PNPs.
- 31 August 2023
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 15 (36) , 42139-42152
Lung Toxicity and Molecular Mechanisms of Lead-Based Perovskite Nanoparticles in the Respiratory System
Extensive applications across diverse fields. However, because of poor stability and relatively strong water solubility, the potential toxicity of Pb-PNPs released into the environment during their manufacture, usage, and disposal has attracted significant attention. Inhalation is a primary route through which human exposure to Pb-PNPs occurs. Herein, the toxic effects and underlying molecular mechanisms of Pb-PNPs in the respiratory system are investigated. The in vitro cytotoxicity of CsPbBr3 nanoparticles in BEAS-2B cells is studied using multiple bioassays and electron microscopy. CsPbBr3 nanoparticles of different concentrations induce excessive oxidative stress and cell apoptosis. Furthermore, CsPbBr3 nanoparticles specifically recruit the TGF-beta(1), which subsequently induces epithelial-mesenchymal transition. In addition, the biodistribution and lung toxicity of representative CsPbBr3 nanoparticles in ICR mice are investigated following intranasal administration. These findings indicate that CsPbBr3 nanoparticles significantly induce pulmonary inflammation and epithelial-mesenchymal transition and can even lead to pulmonary fibrosis in mouse models. Above findings expose the adverse effects and molecular mechanisms of Pb-PNPs in the lung, which broadens the safety data of Pb-PNPs.